Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Urine Test Diagnoses River Blindness Infection

By LabMedica International staff writers
Posted on 11 Mar 2013
A telltale molecular marker for onchocerciasis or river blindness has been discovered that may lead to a potential field test. More...


The newly discovered biomarker is secreted by Onchocerca volvulus worms during an active infection and as it is detectable in patients' urine, and it could form the basis of a portable, field-ready test with significant advantages over current diagnostic methods.

Scientists at The Scripps Research Institute (La Jolla, CA, USA) analyzed onchocerciasis-positive urine samples that were collected in characterized endemic areas in Africa, and their status was confirmed by either positive skin snip (microfilaria-positive) or nodule palpation (nodule-positive). O. volvulus negative urine control samples were also obtained from healthy donors from the USA.

The investigators used liquid chromatography-mass spectroscopy based urine metabolome analysis for the identification of a diagnostic marker of O. volvulus that appears only during an active, microfilariae-producing infection and that could determine both the presence and the severity of disease. They measured the concentrations of hundreds of small-molecule metabolites in the samples and found a unique biomarker, a neurotransmitter derived secretion metabolite from O. volvulus, called N-acetyltyramine-O,β-glucuronide (NATOG).

In urine samples from Africans with active onchocerciasis infections, the scientists found that levels of the biomarker were on average four to six times higher than in samples from Africans with nonactive infections. In a separate test, the team determined that a full course of doxycycline treatment, which sterilizes or kills infecting worms by destroying their symbiotic bacteria, Wolbachia pipientis, also reduced levels of the biomarker to near-normal. The metabolome-mining approach in theory should be applicable to the development of diagnostic tests for other worm diseases.

Daniel Globisch, PhD, the senior author of the study, said, "This biomarker appears to be specific for an active infection, The wide gap between biomarker levels in active and non-active infections suggests that a field test based on the biomarker would be robustly useful." Kim D. Janda, PhD, a professor at Scripps said, " Ultimately for this to be of value in Third World countries we will need to morph this biomarker into something that's inexpensive, simple to use, tolerant of extreme temperatures and portable, basically distilling our finding to a test that can be carted around in a backpack." The study was published on February 25, 2013, in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:

The Scripps Research Institute



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.